Published in J Psychopharmacol on February 08, 2010
The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. PLoS One (2015) 1.40
Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev (2014) 1.37
Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther (2010) 1.09
Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur J Pharmacol (2011) 0.96
Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design. Adv Pharmacol (2014) 0.95
Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. Psychopharmacology (Berl) (2011) 0.94
Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.93
Cocaine self-administration in dopamine D₃ receptor knockout mice. Exp Clin Psychopharmacol (2012) 0.90
Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. J Med Chem (2015) 0.88
Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nucl Med Biol (2011) 0.88
Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys. Neuropharmacology (2015) 0.87
Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development. Neuropharmacology (2013) 0.85
Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys. Neuropsychopharmacology (2015) 0.84
Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. Front Pharmacol (2014) 0.84
Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. Eur Neuropsychopharmacol (2014) 0.83
Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys. Neuropsychopharmacology (2015) 0.83
Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats. Neuropharmacology (2013) 0.82
Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats. Drug Alcohol Depend (2013) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Front Aging Neurosci (2014) 0.82
Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats. Neuropharmacology (2012) 0.80
Dopamine D3 receptors regulate reconsolidation of cocaine memory. Neuroscience (2013) 0.79
Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J Pharmacol Exp Ther (2010) 0.79
Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Front Neurosci (2016) 0.78
Dopamine D1 and D3 receptors mediate reconsolidation of cocaine memories in mouse models of drug self-administration. Neuroscience (2014) 0.78
Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55. J Pharmacol Exp Ther (2013) 0.78
The selective dopamine D3 receptor antagonist, SR 21502, reduces cue-induced reinstatement of heroin seeking and heroin conditioned place preference in rats. Drug Alcohol Depend (2015) 0.78
The selective D₃ receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preference. Synapse (2013) 0.78
Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making. J Neurosci (2016) 0.77
Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia. Eur J Pharmacol (2014) 0.77
A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice. Acta Pharmacol Sin (2015) 0.76
Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder. Ann N Y Acad Sci (2016) 0.76
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. J Med Chem (2016) 0.76
Opposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats. Exp Clin Psychopharmacol (2016) 0.75
Nucleus accumbens hyperpolarization-activated cyclic nucleotide-gated channels modulate methamphetamine self-administration in rats. Psychopharmacology (Berl) (2016) 0.75
The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry (2005) 12.53
Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci (2006) 12.37
Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods (1996) 6.41
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (1990) 6.18
How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) (2001) 6.00
Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev (2002) 4.23
The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev (2005) 3.17
Addictive drugs and brain stimulation reward. Annu Rev Neurosci (1996) 3.12
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature (1999) 2.89
A range of research-based pharmacotherapies for addiction. Science (1997) 2.75
Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science (1996) 2.68
Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol (2005) 2.32
Classical conditioning in drug-dependent humans. Ann N Y Acad Sci (1992) 2.28
A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav (1997) 2.28
Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology (Berl) (1998) 2.27
Management of cocaine abuse and dependence. N Engl J Med (1996) 2.24
Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci (2000) 1.96
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry (2005) 1.94
Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology (1999) 1.94
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci (2002) 1.84
The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev (2005) 1.80
Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem (2005) 1.77
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets (2006) 1.74
Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem (2005) 1.74
Forebrain substrates of reward and motivation. J Comp Neurol (2005) 1.72
The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology (2005) 1.69
Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther (2005) 1.59
Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict (2007) 1.59
Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther (2000) 1.56
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther (2000) 1.56
Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology (Berl) (1989) 1.55
Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci (2000) 1.55
Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse (2005) 1.43
Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology (2002) 1.43
Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci (2005) 1.37
Stress and relapse to drug seeking in rats: studies on the generality of the effect. Psychopharmacology (Berl) (2000) 1.36
Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) (2004) 1.32
The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl) (2007) 1.30
What we have learned about addiction from animal models of drug self-administration. Am J Addict (2000) 1.27
Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev (2007) 1.21
Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther (2000) 1.20
Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology (2005) 1.18
The role of corticosterone in food deprivation-induced reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl) (2002) 1.17
Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology (2003) 1.14
Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry (2008) 1.14
Differential control over drug-seeking behavior by drug-associated conditioned reinforcers and discriminative stimuli predictive of drug availability. Behav Neurosci (2003) 1.12
Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse (2003) 1.11
Brain stimulation reward "thresholds" self-determined in rat. Psychopharmacologia (1960) 1.09
The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav (2005) 1.09
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol (2006) 1.06
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol (2007) 1.04
The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol (1992) 1.03
A labor-supply analysis of cocaine self-administration under progressive-ratio schedules: antecedents, methodologies, and perspectives. Psychopharmacology (Berl) (2000) 0.98
The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology (2009) 0.98
Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology (2009) 0.98
Reinstatement of heroin-reinforced behavior following long-term extinction: implications for the treatment of relapse to drug taking. Behav Pharmacol (1994) 0.96
Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica (2001) 0.96
The dopamine D3 receptor and drug addiction. Neurotox Res (2001) 0.95
Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res (1998) 0.95
Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse (2004) 0.92
Effects of D1 and D2 dopamine receptor antagonists on cocaine-induced self-stimulation and locomotor activity in rats. Eur Neuropsychopharmacol (1999) 0.90
Brain-stimulation reward, morphine-induced oral stereotypy, and sensitization: implications for abuse. Neurosci Biobehav Rev (2004) 0.89
Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport (2003) 0.88
Synergistic effects of cocaine with lateral hypothalamic brain stimulation reward: lack of tolerance or sensitization. J Pharmacol Exp Ther (1997) 0.85
The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward. Brain Res (1994) 0.85
Fitting intracranial self-stimulation data with growth models. Behav Neurosci (1987) 0.84
A comparison of the reinforcing efficacy of PCP, the PCP derivatives TCP and BTCP, and cocaine using a progressive ratio schedule in the rat. Behav Pharmacol (1995) 0.81
SB-277011 GlaxoSmithKline. Curr Opin Investig Drugs (2001) 0.79
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci (2002) 3.40
The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci (2008) 2.72
Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol (2007) 2.64
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci (2002) 1.84
The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev (2005) 1.80
Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem (2005) 1.77
Agents in development for the management of cocaine abuse. Drugs (2004) 1.77
Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem (2005) 1.74
The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology (2005) 1.69
Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther (2005) 1.59
Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 1.54
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci (2005) 1.49
Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci (2006) 1.46
Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther (2004) 1.44
Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse (2005) 1.43
Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci (2005) 1.37
Cocaine-induced brain activation detected by dynamic manganese-enhanced magnetic resonance imaging (MEMRI). Proc Natl Acad Sci U S A (2007) 1.36
Chemosensory factors influencing alcohol perception, preferences, and consumption. Alcohol Clin Exp Res (2003) 1.35
Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) (2004) 1.32
Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther (2008) 1.31
The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl) (2007) 1.30
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J Neurosci (2009) 1.26
Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci (2003) 1.25
Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology (2007) 1.21
Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev (2007) 1.21
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20
N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J Med Chem (2011) 1.20
Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons. J Biol Chem (2010) 1.17
YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol (2011) 1.16
Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther (2005) 1.14
Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther (2009) 1.13
R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry (2012) 1.12
Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem (2009) 1.11
The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology (2010) 1.11
Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse (2003) 1.11
Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther (2010) 1.09
Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter. J Biol Chem (2012) 1.09
The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav (2005) 1.09
Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter. J Med Chem (2005) 1.07
Activation of mGluR7s inhibits cocaine-induced reinstatement of drug-seeking behavior by a nucleus accumbens glutamate-mGluR2/3 mechanism in rats. J Neurochem (2010) 1.07
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol (2005) 1.07
Effects of selective dopaminergic compounds on a delay-discounting task. Behav Pharmacol (2011) 1.06
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol (2006) 1.06
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol (2007) 1.04
Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. Bioorg Med Chem Lett (2006) 1.04
Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 1.04
N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology (2009) 1.03
Labeling of dopamine transporter transmembrane domain 1 with the tropane ligand N-[4-(4-azido-3-[125I]iodophenyl)butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane implicates proximity of cocaine and substrate active sites. Mol Pharmacol (2008) 1.03
Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) (2008) 1.02
The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology (Berl) (2013) 1.02
Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Res (2009) 1.02
N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. J Pharmacol Exp Ther (2010) 1.01
Differential rearing conditions alter operant responding for ethanol in outbred rats. Alcohol Clin Exp Res (2007) 1.01
Levo-tetrahydropalmatine inhibits cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropharmacology (2007) 1.01
Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: involvement of a ventral pallidal GABAergic mechanism. Neuropsychopharmacology (2009) 1.00
Low doses of naltrexone reduce palatability and consumption of ethanol in outbred rats. Alcohol (2002) 1.00
Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J Pharmacol Exp Ther (2005) 1.00
Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther (2003) 1.00
The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav (2008) 1.00
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology (2009) 1.00
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob Agents Chemother (2008) 0.99
The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology (2009) 0.98
Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology (2009) 0.98
The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats. Neuropharmacology (2007) 0.97
Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol (2003) 0.97
Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur J Pharmacol (2011) 0.96
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther (2009) 0.96